Bi-directional actions of estrogen on the renin-angiotensin system

Brazilian Journal of Medical and Biological Research

Volumn 32, Issue 4, 1999, Pages 373-381

  Brosnihan, K B ^a   Senanayake, P S ^b   Li, P ^a   Ferrario, C M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angiotensin converting enzyme; Angiotensin peptides; Angiotensin receptors; Bradykinin; Hormone replacement; Kinins; Nitric oxide; Renin; Vasodilation

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN;

ANGIOTENSIN BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; ENZYME ACTIVITY; ESTROGEN THERAPY; NONHUMAN; PEPTIDE SYNTHESIS; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALIA; EQUIDAE;

EID: 0032930140     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X1999000400001     Document Type: Review

References (72)

1. Wentz AC (1994). Women's health issues. In: Wentz AC (Editor), Advances in Internal Medicine. Mosby-Year Book, Inc. St. Louis, MO, 1-30.
2. Castelli WP (1988). Cardiovascular disease in women. American Journal of Obstetrics and Gynecology, 158: 1553-1560.
3. Pennisi E (1997). Differing roles found for estrogen's two receptors. Science, 277: 1439.
4. Ross RK, Mack TM, Paganini-Hill A, Arthur M & Henderson BE (1981). Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet, 1 (8225): 858-860.
5. Maynard C & Weaver WD (1992). Treatment of women with acute MI: New findings from the MITI registry. Journal of Myocardial Ischemia, 4: 27-37.
6. Keresztes PA & Dan AJ (1992). Estrogen and cardiovascular disease. Cardiovascular Nursing, 28: 1-6.
7. Stamper MJ, Colditz GA, Willett WC, Manson JAE, Rosner B, Speizer FE & Hennekens CH (1991). Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses' health study. New England Journal of Medicine, 325: 756-762.
8. Stevenson JC, Crook D, Godsland IF, Collins P & Whitehead MI (1994). Hormone replacement therapy and the cardiovascular system. Drugs, 47: 35-41.
9. Williams JK, Honore EK, Washburn SA & Clarkson TB (1994). Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. Journal of the American College of Cardiology, 24: 1757-1761.
10. Gisclard V, Miller VM & Vanhoutte PM (1988). Effect of 17-ß estradiol on endothelium-dependent responses in the rabbit. Journal of Pharmacology and Experimental Therapeutics, 244: 19-22.
11. Kauser K & Rubanyi GM (1994). Gender difference in bioassayable endothelium-derived nitric oxide from isolated rat aortae. American Journal of Physiology, 267: H2311-H2317.
12. Li P, Ferrario CM, Ganten D & Brosnihan KB (1997). Chronic estrogen treatment in female transgenic (mRen2)27 hypertensive rats augments endothelium-derived nitric oxide release. American Journal of Hypertension, 10: 662-670.
13. Barrett-Connor E & Bush TL (1991). Estrogen and coronary heart disease in women. Journal of the American Medical Association, 265: 1861-1867.
14. Kolata G (1983). New puzzles over estrogen and heart disease. Science, 220: 1137-1138.
15. PEPI Trial Working Group (1995). Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in post menopausal woman. Journal of the American Medical Association, 273: 199-208.
16. Peach MJ & Levens NR (1980). Molecular Approaches to the Study of Angiotensin Receptors. Plenum Press, New York, 171-194.
17. Bumpus FM & Smeby RR (1962). Importance of amino acid side groups for biologic activity of angiotensin II. Circulation, 25: 183-185.
18. Jaiswal N, Diz DI, Tallant EA, Khosla MC & Ferrario CM (1991). The non-peptide angiotensin II antagonist DuP 753 is a potent stimulus for prostacyclin release. American Journal of Hypertension, 4: 228-233.
19. Jaiswal N, Tallant EA, Diz DI, Khosla MC & Ferrario CM (1991). Subtype 2 angiotensin receptors mediate prostaglandin synthesis in human astrocytes. Hypertension, 17: 1115-1120.
20. Jaiswal N, Diz DI, Tallant EA, Khosla MC & Ferrario CM (1991). Characterization of angiotensin receptors mediating prostaglandin synthesis in C6 glioma cells. American Journal of Physiology, 260: R1000-R1006.
21. Tallant EA, Jaiswal N, Diz DI & Ferrario CM (1991). Human astrocytes contain two distinct angiotensin receptor subtypes. Hypertension, 18: 32-39.
22. Tallant EA, Diz DI, Khosla MC & Ferrario CM (1991). Identification and regulation of angiotensin II receptor subtypes on NG108-15 cells. Hypertension, 17: 1135-1143.
23. Li P, Chappell MC, Ferrario CM & Brosnihan KB (1997). Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension, 29: 394-400.
24. Osei SY, Ahima RS, Minkes RK, Weaver JP, Khosla MC & Kadowitz PJ (1993). Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. European Journal of Pharmacology, 234: 35-42.
25. Porsti I, Bara AT, Busse R & Hecker M (1994). Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. British Journal of Pharmacology, 111: 652-654.
26. Brosnihan KB, Li P & Ferrario CM (1996). Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension, 27: 523-528.
27. MacGregor GA, Markandu ND, Roulston JE, Jones JC & Morton JJ (1981). Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature, 291: 329-331.
28. Laragh JH (1992). The renin system and four lines of hypertension research: nephron heterogeneity, the calcium connection, the prorenin vasodilator limb, and plasma renin and heart attack. Hypertension, 20: 267-279.
29. Mullins JJ, Peters J & Ganten D (1990). Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature, 344: 541-544.
30. Hall JE & Brands MW (1992). The reninangiotensin-aldosterone systems - Renal mechanisms and circulatory homeostasis. In: Seldin DW & Giebisch G (Editors), The Renin-Angiotensin-Aldosterone Systems. 2nd edn. Raven Press Ltd., New York, 1455-1504.
31. Hall JE, Mizelle HL, Brands MW & Hildebrandt DA (1992). Pressure natriuresis and angiotensin II in reduced kidney mass, salt-induced hypertension. American Journal of Physiology, 262: R61-R71.
32. Bravo EL, Tarazi RC & Dustan HP (1977). Multifactorial analysis of chronic hypertension induced by electrolyte-active steroids in trained unanesthetized dogs. Circulation Research, 40 (Suppl I): 140-145.
33. Gordon RD, Klemm SA, Tunny TJ & Stowasser M (1992). Primary aldosteronism: Hypertension with a genetic basis. Lancet, 340: 159-161.
34. Genest J, Nowaczynski W, Kuchel O, Boucher R & Rojo-Ortega JM (1977). The role of the adrenal cortex in human essential hypertension. Mayo Clinic Proceedings, 52: 291-307.
35. Welches WR, Brosnihan KB & Ferrario CM (1993). A comparison of the properties, and enzymatic activity of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sciences, 52: 1461-1480.
36. Kohara K, Brosnihan KB & Ferrario CM (1993). Angiotensin-(1-7) in the spontaneously hypertensive rat. Peptides, 14: 883-891.
37. Santos RAS, Brosnihan KB, Jacobsen DW, DiCorleto PE & Ferrario CM (1992). Production of angiotensin-(1-7) by human vascular endothelium. Hypertension, 19 (Suppl II): II-56-II-61.
38. Campbell DJ, Kladis A & Duncan AM (1994). Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension, 23: 439-449.
39. Iyer SN, Chappell MC, Averill DB, Diz DI & Ferrario CM (1998). Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension, 31: 699-705.
40. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB & Diz DI (1997). Counter-regulatory actions of angiotensin-(1-7). Hypertension, 30: 535-541.
41. Benter I, Ferrario CM, Morris M & Diz DI (1995). Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. American Journal of Physiology, 269: H313-H319.
42. Ferrario CM, Brosnihan KB, Tallant EA & Diz DK (1995). Angiotensin-(1-7). A novel hormone of the RAS. American Journal of Hypertension, 8: 28 (Abstract).
43. Brosnihan KB, Santos RAS, Block CH, Schiavone MT, Welches WR, Chappell MC, Khosla MC, Greene LJ & Ferrario CM (1988). Biotransformation of angiotensins in the central nervous system. Therapeutic Research, 9: 48-59.
44. Ferrario CM & Chappell MC (1994). A new myocardial conversion of angiotensin I. Current Opinion in Cardiology, 9: 520-526.
45. Yamamoto K, Chappell MC, Brosnihan KB & Ferrario CM (1992). In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension, 19: 692-696.
46. Chappell MC, Tallant EA, Brosnihan KB & Ferrario CM (1994). Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC 3.4.24.15) in vascular smooth muscle cells. Journal of Vascular Medicine and Biology, 5: 129-137.
47. Sardinia MF, Hanesworth JM, Krebs LT & Harding JW (1993). AT4 receptor binding characteristics: D-amino acid-and glycine-substituted peptides. Peptides, 14: 949-954.
48. Hanesworth JM, Sardinia MF, Krebs LT, Hall KL & Harding JW (1993). Elucidation of a specific binding site for angiotensin II 13-8), angiotensin IV, in mammalian heart membranes. Journal of Pharmacology and Experimental Therapeutics, 266: 1036-1042.
49. Chappell MC, Pirro NT, Sykes A & Ferrario CM (1998). Metabolism of angiotensin-(1-7) by angiotensin converting enzyme. Hypertension, 31: 362-367.
50. 1-7 and Keto-ACE. Hypertension. 30: 494 (Abstract).
51. Nasjletti A & Masson GMC (1972). Studies on angiotensinogen formation in a liver perfusion system. Circulation Research, 30 (Suppl II): 187-202
52. Tewksbury DA (1990). Angiotensinogen -biochemistry and molecular biology. In: Laragh JH & Brenner BM (Editors), Hypertension: Pathophysiology, Diagnosis and Management. Raven Press, New York, 1197-1216.
53. Chen Y, Naftilan AJ & Oparil S (1992). Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension, 19: 456-463.
54. Rubattu S, Quimby FW & Sealey JE (1991). Tissue renin and prorenin increase in female cats during the reproductive cycle without commensurate changes in plasma, amniotic or ovarian follicular fluid. Journal of Hypertension, 9: 525-535.
55. Glorioso N, Atlas SA, Laragh JH, Jewelewicz R & Sealey JE (1986). Prorenin in high concentrations in human ovarian follicular fluid. Science, 233: 1422-1424.
56. Howard RB, Pucell AG, Bumpus FM & Husain A (1988). Rat ovarian renin: Characterization and changes during the estrous cycle. Endocrinology, 123: 2331-2340.
57. Alhenc-Gelas F, Tache A, Saint-Andre JP, Milliez J, Sureau C, Corvol P & Menard J (1986). The renin-angiotensin system in pregnancy and parturition. Year Book Medical Publishers, Inc., Chicago, IL, 25-33.
58. Jespersen CM, Arnung K, Hagen C, Hilden T, Nielsen F, Nielsen MD & Giese J (1983). Effects of natural oestrogen therapy on blood pressure and renin-angiotensin system in normotensive and hypertensive menopausal women. Journal of Hypertension, 1: 361-364.
59. Oelkers WKH (1996). Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids, 61: 166-171.
60. Cain MD, Walters WA & Catt KJ (1971). Effects of oral contraceptive therapy on the renin-angiotensm system. Journal of Clinical Endocrinology, 33: 671-676.
61. Sealey JE, Choisi I, Glorioso N, Troffa C, Weintraub ID, James G & Laragh JH (1987). Sequential changes in plasma luteinizing hormone and plasma prorenin during the menstrual cycle. Journal of Clinical Endocrinology and Metabolism, 63: 1.
62. Brosnihan KB, Li P, Ganten D & Ferrario CM (1997). Estrogen protects transgenic hypertensive rats by shifting the vasoconstrictor-vasodilator balance of RAS. American Journal of Physiology, 273: R1908-R1915.
63. Dunne FP, Barry DG, Ferriss JB, Grealy G & Murphy D (1991). Changes in blood pressure during the normal menstrual cycle. Clinical Science, 81: 515-518.
64. Pfeffer RI, Kurosaki TT & Charlton SK (1979). Estrogen use and blood pressure in later life. American Journal of Epidemiology, 110: 469-478.
65. Williams JK, Anthony MS, Honore EK, Herrington DM, Morgan TM, Register TC & Clarkson TB (1995). Regression of atherosclerosis in female monkeys. Arteriosclerosis, Thrombosis, and Vascular Biology, 15: 827-836.
66. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B, Graf P & Brunner HR (1990). Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension, 16: 564-572.
67. Kaplan NM (1995). The treatment of hypertension in women. Archives of Internal Medicine, 155: 563-567.
68. Long D & Evans R (1922) Mammalian reproduction. Memoir of the University of California, 6: 1-148.
69. Senanayake PD, Moriguchi A, Kumagai H, Ganten D, Ferrario CM & Brosnihan KB (1994). Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. Peptides, 15: 919-926.
70. Wenger NK (1995). Hypertension and other cardiovascular risk factors in women. American Journal of Hypertension, 8: 94S-99S
71. Cacciabaudo JM & Sealey JE (1994). Hormone replacement therapy and hypertension: Relationship to the renin-angiotensm system. In: Safar M, Stimpel M & Zanchetti A (Editors), Hypertension in Postmenopausal Women. Springer-Verlag, Berlin, Heidelberg, 53-63.
72. Brosnihan KB, Weddle D, Anthony MS, Heise C, Li P & Ferrario CM (1997). Effects of chronic hormone replacement on the renin-angiotensm system in cynomolgus monkeys. Journal of Hypertension, 15: 719-726.